CNS Pharmaceuticals (CNSP) Price & Analysis

Q: What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?

Cns Pharmaceuticals, Inc. lowest stock price was $4.93 and its highest was $114.00 in the past 12 months.

Q: What is Cns Pharmaceuticals, Inc.’s market cap?

Cns Pharmaceuticals, Inc.’s market cap is $4.04M.

Q: When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?

Cns Pharmaceuticals, Inc.’s upcoming earnings report date is May 18, 2026 which is in 163 days.

Q: How were Cns Pharmaceuticals, Inc.’s earnings last quarter?

Cns Pharmaceuticals, Inc. released its earnings results on Nov 12, 2025. The company reported -$5.76 earnings per share for the quarter, beating the consensus estimate of -$6.63 by $0.87.

Q: Is Cns Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Q: Does Cns Pharmaceuticals, Inc. pay dividends?

Cns Pharmaceuticals, Inc. does not currently pay dividends.

Q: What is Cns Pharmaceuticals, Inc.’s EPS estimate?

Cns Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

Q: How many shares outstanding does Cns Pharmaceuticals, Inc. have?

Cns Pharmaceuticals, Inc. has 620,290 shares outstanding.

Q: What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?

Cns Pharmaceuticals, Inc. reported an EPS of -$5.76 in its last earnings report, beating expectations of -$6.63. Following the earnings report the stock price went down -2.08%.

Q: Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in CNSP

Compare

1,088 Followers

CNSP Stock Chart & Stats

$9.20

<$0.01(4.42%)

At close: Jan 08 4:00 PM EST

$9.20

<$0.01(4.42%)

Day’s Range― - ―

52-Week Range$4.93 - $114.00

Previous CloseN/A

Volume19.26M

Average Volume (3M)13.39K

Market Cap

$4.04M

Enterprise Value-$4.80M

Total Cash (Recent Filing)$9.86M

Total Debt (Recent Filing)$30.79K

Price to Earnings (P/E)―

Beta2.29

Next Earnings

May 18, 2026

EPS EstimateN/A

Next Dividend Ex-DateN/A

Dividend YieldN/A

Share Statistics

EPS (TTM)-5.76

Shares Outstanding620,290

10 Day Avg. Volume6,352

30 Day Avg. Volume13,386

Financial Highlights & Ratios

PEG Ratio0.04

Price to Book (P/B)3.71

Price to Sales (P/S)0.00

P/FCF Ratio-1.34

Enterprise Value/Market Cap-1.19

Enterprise Value/RevenueN/A

Enterprise Value/Gross Profit1.24K

Enterprise Value/Ebitda0.37

Forecast

1Y Price Target

$20.00

Price Target Upside117.39% Upside

Rating ConsensusModerate Buy

Number of Analyst Covering1

EPS Forecast (FY)-31.41

Revenue Forecast (FY)$23.20M

Bulls Say, Bears Say

Bulls Say

Clinical TrialsTPI-287 demonstrated an overall response rate of 60% in a Phase 1 trial for rGBM, with a 96% disease control rate, indicating promising efficacy.

Regulatory ProspectsThe totality of data could support a formal discussion with the FDA around a potential filing or accelerated approval pathway for Berubicin without another trial.

Strategic DevelopmentCNS Pharmaceuticals is upgrading shares to Buy due to the pivot to its oncology asset TPI-287, which is in development for recurrent glioblastoma (rGBM).

Bears Say

Market PerformanceCNS Pharmaceuticals shares are at an all-time low due to the Berubicin trial missing its primary endpoint in March.

Trial ResultsBerubicin’s trial did not meet the primary OS endpoint, causing uncertainty about its effectiveness.

CNS Pharmaceuticals News

CNS Pharmaceuticals reports Q3 EPS ($5.76) vs. ($153.20) last year

“As we head into the final quarter of the year, our mission remains centered on delivering meaningful developments...

19d ago

CNSP

CNS Pharmaceuticals sees cash runway into 2H26

As of September 30, 2025, the Company had cash of approximately $9.9 million. While trial costs are difficult...

19d ago

CNSP

CNS Pharmaceuticals Increases Authorized Shares for Growth

CNS Pharmaceuticals ( ($CNSP) ) just unveiled an update. On November 17, 2025, CNS Pharmaceuticals held its Annual...

14d ago

CNSP

CNS Pharmaceuticals: Promising Drug Pipeline and Strategic Plans Drive Buy Rating

Jason McCarthy, an analyst from Maxim Group, maintained the Buy rating on CNS Pharmaceuticals. The associated price target...

17d ago

CNSP

CNS Pharmaceuticals Reports Financial Gains Amid Ongoing R&D

Cns Pharmaceuticals, Inc. ( ($CNSP) ) has released its Q3 earnings. Here is a breakdown of the information...

18d ago

CNSP

CNS Pharmaceuticals upgraded to Buy at Maxim on TPI-287 roadmap

As previously reported, Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target The...

3M ago

CNSP

CNS Pharmaceuticals upgraded to Buy from Hold at Maxim

Maxim upgraded CNS Pharmaceuticals (CNSP) to Buy from Hold with a $20 price target Published first on TheFly...

3M ago

CNSP

CNS Pharmaceuticals reports Q2 EPS ($6.42) vs. ($4,049.20) last year

“Every decision we make is grounded in our science and driven by a sense of urgency and responsibility...

4M ago

CNSP

CNS Pharmaceuticals sees cash runway into 2H26

As of June 30, 2025, the Company had cash of approximately $12.1 million. The Company believes that the...

4M ago

CNSP

CNS Pharmaceuticals Reports Q2 2025 Financial Results

Cns Pharmaceuticals, Inc. ( ($CNSP) ) has released its Q2 earnings. Here is a breakdown of the information...

4M ago

CNSP

CNS Pharmaceuticals Announces Reverse Stock Split

CNS Pharmaceuticals ( ($CNSP) ) has shared an announcement. On July 17, 2025, CNS Pharmaceuticals, Inc. announced a...

5M ago

CNSP

CNS Pharmaceuticals Inc trading halted, news pending

19:50 EDT CNS Pharmaceuticals (CNSP) Inc trading halted, news pending Published first on TheFly – the ultimate source...

5M ago

CNSP

Upcoming Stock Splits This Week (July 21 to July 25) – Stay Invested

These are the upcoming stock splits for the week of July 21 to July 25 on TipRanks’ Stock Splits...

5M ago

GVH

CNS Pharmaceuticals announces 1-for-12 reverse stock split

CNS Pharmaceuticals (CNSP) announced a 1-for-12 reverse split of its common stock. Beginning on July 22, 2025, the...

5M ago

CNSP

CNSP FAQ

What was Cns Pharmaceuticals, Inc.’s price range in the past 12 months?

Cns Pharmaceuticals, Inc. lowest stock price was $4.93 and its highest was $114.00 in the past 12 months.

What is Cns Pharmaceuticals, Inc.’s market cap?

Cns Pharmaceuticals, Inc.’s market cap is $4.04M.

When is Cns Pharmaceuticals, Inc.’s upcoming earnings report date?

Cns Pharmaceuticals, Inc.’s upcoming earnings report date is May 18, 2026 which is in 163 days.

How were Cns Pharmaceuticals, Inc.’s earnings last quarter?

Cns Pharmaceuticals, Inc. released its earnings results on Nov 12, 2025. The company reported -$5.76 earnings per share for the quarter, beating the consensus estimate of -$6.63 by $0.87.

Is Cns Pharmaceuticals, Inc. overvalued?

According to Wall Street analysts Cns Pharmaceuticals, Inc.’s price is currently Undervalued. Get more investment ideas with TipRanks Premium

Does Cns Pharmaceuticals, Inc. pay dividends?

Cns Pharmaceuticals, Inc. does not currently pay dividends.

What is Cns Pharmaceuticals, Inc.’s EPS estimate?

Cns Pharmaceuticals, Inc.’s EPS estimate for its next earnings report is not yet available.

How many shares outstanding does Cns Pharmaceuticals, Inc. have?

Cns Pharmaceuticals, Inc. has 620,290 shares outstanding.

What happened to Cns Pharmaceuticals, Inc.’s price movement after its last earnings report?

Cns Pharmaceuticals, Inc. reported an EPS of -$5.76 in its last earnings report, beating expectations of -$6.63. Following the earnings report the stock price went down -2.08%.

Which hedge fund is a major shareholder of Cns Pharmaceuticals, Inc.?

Currently, no hedge funds are holding shares in CNSP

Company Description

Cns Pharmaceuticals, Inc.

CNS Pharmaceuticals, Inc. is a biotechnology company focused on developing novel treatments for brain tumors. The company is particularly dedicated to advancing its lead drug candidate, Berubicin, which is being investigated for the treatment of glioblastoma multiforme, a highly aggressive form of brain cancer. CNS Pharmaceuticals operates in the biopharmaceutical sector and is committed to addressing unmet medical needs through innovative research and development.

CNS Pharmaceuticals (CNSP) Earnings & Revenues

Historic Earnings Reports

CNSP Stock 12 Month Forecast

Average Price Target

$20.00

▲(117.39% Upside)

{"navigator":{"disabled":true},"exporting":{"enabled":false},"title":{"text":null},"chart":{"height":200,"style":{"fontFamily":"Roboto Flex, -apple-system, BlinkMacSystemFont, Segoe UI, Roboto, Helvetica, Arial, sans-serif, Apple Color Emoji, Segoe UI Emoji, Segoe UI Symbol","fontWeight":"400","color":"#5d5d5e"},"spacingTop":30,"spacingRight":60,"events":null},"yAxis":{"labels":{"style":{"color":"inherit"},"distance":6,"x":-6,"y":-6,"zIndex":1,"map_label_formatter":{"6":"$6","1530001":"$1,530,001","382504.75":"$382,504.8","765003.5":"$765,003.5","1147502.25":"$1,147,502.3"}},"plotLines":[{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":-10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-bottom flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#199ca5\">High </span>\n\n  <span style=\"color:#199ca5\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":0,"text":"<div  class=\"positionrelative hoverZ3 triangleleft flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#828080\">Average </span>\n\n  <span style=\"color:#828080\">$20.00</span>\n  </div></div>","useHTML":true}},{"color":"rgba(0,0,0,0)","value":20,"label":{"className":" overflowvisible_force","align":"right","x":60,"y":10,"text":"<div  class=\"positionrelative hoverZ3 triangleleft-top flexccc bgwhite shadowhard-3 border1 borderColorwhite-8 colorwhite-8 px2 lineHeight3 fontWeightsemibold fontSize10 radiismall h_pxsmall35\"> <div class=\"w_pxsmall60 flexccc\">\n  <span style=\"color:#912767\">Low </span>\n\n  <span style=\"color:#912767\">$20.00</span>\n  </div></div>","useHTML":true}}],"tickPositions":[6,382504.75,765003.5,1147502.25,1530001],"lineColor":"#dddddd","gridLineWidth":1,"gridLineColor":"#dddddd","lineWidth":1,"title":{"text":""}},"plotOptions":{"series":{"states":{"inactive":{"opacity":1}}},"line":{"animation":{"duration":0},"dataLabels":{"allowOverlap":true},"borderWidth":1,"marker":{"enabled":true,"fillColor":"#FFFFFF","radius":3,"lineWidth":2,"symbol":"circle","lineColor":"#828080"}}},"xAxis":{"labels":{"style":{"color":"inherit"},"rotation":0,"map_label_formatter":{"3":"Aug<br/>2022","6":"Nov<br/>2024","9":"Mar<br/>2025","12":"Nov<br/>2025","25":"Nov<br/>2026"}},"tickPositions":[3,6,9,12,25],"plotLines":[{"color":"#dddddd","width":1,"value":12},{"color":"#dddddd","width":1,"value":12}],"lineWidth":0,"gridLineWidth":1,"gridLineColor":"#dddddd","tickLength":0},"legend":{"symbolRadius":0,"symbolPadding":4,"symbolHeight":14,"borderWidth":0,"symbolWidth":14,"align":"left","verticalAlign":"bottom","enabled":false},"tooltip":{"backgroundColor":"rgba(0,0,0,0)","useHTML":true,"borderWidth":0,"borderColor":"rgba(0,0,0,0)","padding":0,"shadow":null,"headerFormat":"","footerFormat":"","pointFormat":"<div class=\"flexccc lineHeight2 bgwhite shadow2 px3 py3 radiismall fonth10_semibold\">\n                <span class=\"colorgray-3 mb4\">{point.date:%b %d ,%Y}</span>\n                <span>Analyst Consensus</span>\n                {point.info}\n          </div>\n           </div>"},"credits":{"enabled":false},"accessibility":{"description":""},"responsive":{"rules":[{"chartOptions":{"chart":{"spacing":[0,0,0,0],"margin":[30,60,40,5]},"xAxis":{"tickPositions":[3,12,25.25]},"yAxis":{"labels":{"enabled":false}},"title":{"text":null},"subtitle":{"text":null}},"condition":{"maxWidth":500}}]},"series":[{"lineWidth":2,"dashStyle":"ShortDash","name":"High","type":"line","color":"#199ca5","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.646153846153846,9.592307692307692,10.538461538461538,11.484615384615385,12.430769230769231,13.376923076923077,14.323076923076924,15.26923076923077,16.215384615384615,17.161538461538463,18.107692307692307,19.053846153846155,{"y":20,"marker":{"fillColor":"#199ca5","lineColor":"#199ca5","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Average","type":"line","color":"#828080","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.646153846153846,9.592307692307692,10.538461538461538,11.484615384615385,12.430769230769231,13.376923076923077,14.323076923076924,15.26923076923077,16.215384615384615,17.161538461538463,18.107692307692307,19.053846153846155,{"y":20,"marker":{"fillColor":"#828080","lineColor":"#828080","enabled":true,"symbol":"circle"}}]},{"lineWidth":2,"dashStyle":"ShortDash","name":"Low","type":"line","color":"#912767","enableMouseTracking":false,"marker":{"enabled":false},"data":[null,null,null,null,null,null,null,null,null,null,null,null,7.7,8.646153846153846,9.592307692307692,10.538461538461538,11.484615384615385,12.430769230769231,13.376923076923077,14.323076923076924,15.26923076923077,16.215384615384615,17.161538461538463,18.107692307692307,19.053846153846155,{"y":20,"marker":{"fillColor":"#912767","lineColor":"#912767","enabled":true,"symbol":"circle"}}]},{"type":"line","data":[{"y":1530000.3,"date":1627776000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":521460,"date":1643673600000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":298980,"date":1651363200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 4,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":198000.03,"date":1659312000000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":48300,"date":1682899200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":94.32,"date":1725148800000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 0</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.56,"date":1730419200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#199ca5","enabled":true,"symbol":"circle"}},{"y":67.14,"date":1733011200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":72.24,"date":1735689600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 0, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 2</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":29.16,"date":1740787200000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":15.48,"date":1743465600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":12.72,"date":1746057600000,"info":" <span style=\"color:#828080\" class=\"mb3 mt2 fonth8_semibold\"> Hold</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 1,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 2, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"lineColor":"#828080","enabled":true,"symbol":"circle"}},{"y":7.7,"date":1761955200000,"info":" <span style=\"color:#199ca5\" class=\"mb3 mt2 fonth8_semibold\"> Strong Buy</span>\n            <div class=\"flexrcb px3 displayflex fonth9_semibold\"><span  style=\"color:#199ca5\">Buy 2,\t&nbsp; </span>\n              <span  style=\"color:#828080\">Hold 1, \t&nbsp;</span>\n              <span  style=\"color:#912767\">Sell 1</span>\n      ","marker":{"fillColor":"black","lineColor":"black","enabled":true,"symbol":"circle"}},null,null,null,null,null,null,null,null,null,null,null,null],"color":"#0666a7"}]}

Detailed Analyst Forecast >